This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid specific interferon-alpha2 expression, which will be administered to up to 27 patients affected by GBM who have an unmethylated MGMT promoter. Part A will evaluate the safety and tolerability of 5 escalating doses of Temferon and 3 different conditioning regimens in up to 27 patients, following first line treatment.

A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT

Genenta Science

The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.

Find clinical trials for Glioblastoma (GBM) in Roma, Lazio

Related conditions:

Glioblastoma (GBM) trials near Roma, Lazio, ITA:

A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT (TEM-GBM)

LAM561 With RT and TMZ for Adults With Glioblastoma (CLINGLIO)

Find clinical trials for Glioblastoma (GBM) in .css-epvm6{white-space:nowrap;}Roma, Lazio

Related conditions:

Glioblastoma (GBM) trials near Roma, Lazio, ITA:

A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT (TEM-GBM)

LAM561 With RT and TMZ for Adults With Glioblastoma (CLINGLIO)

Find clinical trials for Glioblastoma (GBM) in Roma, Lazio